Salvia BioElectronics implants first patient in pivotal U.S. migraine study
Salvia BioElectronics has reached an important milestone in the development of its migraine therapy. The first patient in the United States has been implanted with the investigational MySalvia System as part of RECLAIM-II, the company’s pivotal clinical study in adults with resistant migraine.
For people living with resistant migraine, finding effective treatment can be a significant challenge. Despite trying multiple preventive therapies, many continue to experience debilitating migraine attacks that affect their daily lives. Salvia is developing a new approach to address this unmet medical need.
The MySalvia System is a minimally invasive neuromodulation therapy designed specifically for migraine prevention. It uses two ultra-thin implants placed just beneath the skin, at the front and back of the head, to target nerves involved in migraine. Patients activate the investigational therapy twice daily using a small wearable device, with the aim of reducing the frequency and severity of migraine attacks.
Building on earlier clinical research in Europe, RECLAIM-II will evaluate the safety and effectiveness of the MySalvia System in approximately 150 patients across more than 20 clinical sites in the United States. The study represents an important step in gathering the clinical evidence needed to assess the potential of this technology for people living with resistant migraine.